Infectious Disease

AstraZeneca’s COVID-19 vaccine exhibits an general effectiveness of 70% with two doses

December 08, 2020

1 min read

Source / information

Disclosure:
Voysey does not report any relevant financial information. In the study you will find all relevant financial information from all other authors.

ADD SUBJECT TO EMAIL ALARMS

Receive an email when new articles are published

Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

Back to Healio

The AstraZeneca and Oxford University COVID-19 vaccine showed an overall effectiveness of 70% after two doses, based on total data from four studies published in The Lancet.

“Here we demonstrated for the first time that a viral vector vaccine, ChAdOx1 nCoV-19, is effective and can help fight the disease in this pandemic.” Merryn Voysey, DPhil, Chief Statistician at the Oxford Vaccine Group, and colleagues wrote.

Covid vaccination

AstraZeneca and Oxford University’s COVID-19 vaccine showed an overall effectiveness of 70% at two doses.
Photo credit: Adobe Stock

An interim analysis of the vaccine from the UK and Brazil previously found an average effectiveness of 70% and no safety concerns.

In the latest study, Voysey and colleagues analyzed data from studies in the UK, Brazil, and South Africa. They included 11,636 patients for the primary efficacy analysis. Patients were randomly assigned to receive either the ChAdOx1 nCoV-19 vaccine or a control vaccine containing saline or meningococcal group A, C, W and Y vaccine. Participants who received the ChAdOx1 vaccine received two doses, but a subgroup of participants in the UK received a half dose first – due to a manufacturing defect, media reported, followed by a standard dose as the second dose.

According to the researchers, the effectiveness of ChAdOx1 was 62.1% (95% CI, 41-75.7) in those given two standard doses and 90% (95% CI, 67.4-97) among the participants who were given half a dose followed by a standard dose.

“Until widespread immunity stops the spread of SARS-CoV-2, physical distancing measures and novel therapies are needed to control COVID-19,” the researchers wrote. “In the meantime, an effective vaccine can have a huge impact on the pandemic if used in populations at risk of serious illness.”

ADD SUBJECT TO EMAIL ALARMS

Receive an email when new articles are published

Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

Back to Healio

COVID-19 Resource Center

COVID-19 Resource Center

Related Articles